Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome

Eur J Ophthalmol. May-Jun 2006;16(3):481-3. doi: 10.1177/112067210601600322.

Abstract

Purpose: To report the results of intravitreal triamcinolone acetonide in two eyes of a patient with Vogt-Koyanagi-Harada syndrome.

Methods: A 24-year-old woman with Vogt-Koyanagi-Harada syndrome was treated with a single 4-mg dose of intravitreal injection of triamcinolone acetonide in both eyes.

Results: On the seventh day after injection, visual acuity improved from 20/50 to 20/20 in the right eye and from 20/100 to 20/32 in the left. One month after injection, visual acuity was 20/20 in the right eye and 20/32 in the left, and fluorescein angiography showed that serous detachment had almost completely resorbed. The ocular examination remained stable during the 8-month follow-up period.

Conclusions: In this study, a prompt improvement in the clinical picture of a patient with Vogt-Koyanagi-Harada syndrome after intravitreal triamcinolone acetonide injection was described. The results suggest that intravitreal triamcinolone acetonide injection may be an additional tool in the treatment of Vogt-Koyanagi-Harada syndrome.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • Fluorescein Angiography
  • Glucocorticoids / therapeutic use*
  • Humans
  • Injections
  • Tomography, Optical Coherence
  • Triamcinolone Acetonide / therapeutic use*
  • Uveomeningoencephalitic Syndrome / diagnosis
  • Uveomeningoencephalitic Syndrome / drug therapy*
  • Visual Acuity
  • Vitreous Body

Substances

  • Glucocorticoids
  • Triamcinolone Acetonide